
PBS advisory committee recommends funding triptorelin for cancer, endometriosis, and gender-affirming care
The Pharmaceutical Benefits Scheme advisory committee has recommended government funding for triptorelin to treat breast cancer, endometriosis, and gender dysphoria, potentially bypassing state-level bans on gender-affirming care in Queensland and the NT.






